Aprea Therapeutics Inc

APRE

Add to Watchlist

0.930USD

-0.011-1.16%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

Aprea Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

98 / 382

Overall Ranking

220 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Aprea Therapeutics Inc Highlights

StrengthsRisks

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company’s pipeline includes two clinical-stage synthetic lethality programs. Its lead programs are APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a small-molecule ATR inhibitor, both in clinical development for solid tumor indications. Its ATRN-119 is an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR). The ATR kinase is a master regulator of Deoxyribonucleic Acid (DNA) damage response, with roles in cell cycle control and DNA repair following replication stress. It is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute. It also has an early-stage program, in the lead optimization stage, for an undisclosed DNA-damage response (DDR) target.

Growing

The company is in a growing phase, with the latest annual income totaling USD 285.76K.

Fairly Valued

The company’s latest PE is -0.62, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 2.34M shares, increasing 18.00% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 0.00 shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.36.

Analyst Rating

Based on 4 analysts

Strong Buy

Current Rating

4.300

Target Price

+356.96%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Aprea Therapeutics Inc is 6.46, ranking 238 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 16.39%.

Score

Industry at a Glance

Previous score

6.46

Change

0



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.74

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.84

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.62

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.08

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Aprea Therapeutics Inc is 8.87, ranking 8 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.62, which is -100.00% below the recent high of 0.00 and -244.24% above the recent low of -2.14.

Score

Industry at a Glance

Previous score

8.87

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 98/382

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Aprea Therapeutics Inc is 8.67, ranking 70 out of 382 in the Biotechnology & Medical Research industry. The average price target is 10.50, with a high of 11.00 and a low of 10.00.

Score

Industry at a Glance

Previous score

8.67

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Aprea Therapeutics Inc is 6.51, ranking 230 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.08 and the support level at 0.78, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.57

Change

-0.06

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Aprea Therapeutics Inc is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 18.86%, representing a quarter-over-quarter decrease of 46.24%. The largest institutional shareholder is James Simons, holding a total of 25.10K shares, representing 0.20% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

AIGH Capital Management, LLC.

270.24K

-29.27%

Lytton (Laurence W)

681.84K

--

Gilad (Oren)

381.46K

+5.58%

Murchinson Ltd.

340.14K

--

Sphera Funds Management Ltd.

270.00K

--

Duey (Marc)

255.71K

+9.16%

Nantahala Capital Management, LLC

205.76K

--

DRW Securities, LLC

120.65K

--

Worth Venture Partners, LLC

100.30K

-36.21%

Morgan Stanley & Co. LLC

76.95K

+17.07%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Aprea Therapeutics Inc is 2.31, ranking 224 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 1.52. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Aprea Therapeutics Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Aprea Therapeutics Inc

APRE

6.51 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.48 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment